Viking Therapeutics (VKTX)

Viking Therapeutics (VKTX) Stock Price & Analysis


VKTX Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$3.54 - $25.72
Previous Close$13.01
Average Volume (3M)2.05M
Market Cap
Enterprise Value$926.47M
Total Cash (Recent Filing)$376.24M
Total Debt (Recent Filing)$1.34M
Price to Earnings (P/E)-14.1
Feb 07, 2024
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.92
Shares Outstanding100,028,953
10 Day Avg. Volume1,455,611
30 Day Avg. Volume2,050,374
Standard Deviation0.24
Financial Highlights & Ratios
Price to Book (P/B)3.53
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.60
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-15.77
Price Target Upside161.34% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6



Ownership Overview

24.99% Mutual Funds
34.42% Other Institutional Investors
31.62% Public Companies and Individual Investors


What was Viking Therapeutics’s price range in the past 12 months?
Viking Therapeutics lowest stock price was $3.54 and its highest was $25.72 in the past 12 months.
    What is Viking Therapeutics’s market cap?
    Currently, no data Available
    When is Viking Therapeutics’s upcoming earnings report date?
    Viking Therapeutics’s upcoming earnings report date is Feb 07, 2024 which is in 65 days.
      How were Viking Therapeutics’s earnings last quarter?
      Viking Therapeutics released its earnings results on Oct 25, 2023. The company reported -$0.23 earnings per share for the quarter, missing the consensus estimate of -$0.219 by -$0.011.
        Is Viking Therapeutics overvalued?
        According to Wall Street analysts Viking Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does Viking Therapeutics pay dividends?
          Viking Therapeutics does not currently pay dividends.
          What is Viking Therapeutics’s EPS estimate?
          Viking Therapeutics’s EPS estimate is -$0.26.
            How many shares outstanding does Viking Therapeutics have?
            Viking Therapeutics has 100,028,950 shares outstanding.
              What happened to Viking Therapeutics’s price movement after its last earnings report?
              Viking Therapeutics reported an EPS of -$0.23 in its last earnings report, missing expectations of -$0.219. Following the earnings report the stock price went down -9.466%.
                Which hedge fund is a major shareholder of Viking Therapeutics?
                Among the largest hedge funds holding Viking Therapeutics’s share is Viking Global Investors LP. It holds Viking Therapeutics’s shares valued at 51M.


                  Company Description

                  Viking Therapeutics

                  Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for patients suffering from metabolic and endocrine disorders. The company's clinical program VK5211, treats patients recovering from non-elective hip fracture surgery. It also specializes in development of VK2809 and VK0214. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.


                  Top 5 ETFs holding VKTX

                  Market Value
                  Smart Score
                  Vanguard Total Stock Market ETF
                  Vanguard Health Care ETF
                  Schwab U.S. Broad Market ETF
                  Vanguard U.S. Momentum Factor ETF
                  Vanguard Russell 3000 ETF
                  Up to five ETFs with an Outperform Smart Score that hold VKTX. The ETFs are listed according to market value of VKTX within the ETF

                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  ACADIA Pharmaceuticals
                  Arrowhead Pharmaceuticals

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis